

April 28-29, 2021
Webinar

Ten years' experience in Radiofrequency Ablation, VENEFIT

Ottorino Del Foco
Stem Cells Center, UAE



Abstract:

From October 2009 to November 2019, 2249 VENEFIT procedures were carried out in 1818 patients by the same surgeon.

431 procedures: 23,7% were bilateral; left safena alone was affected in 857 patients while right safena in 530. Sex distribution was females: 1421 (78,1%); males: 397 (21,9%) Average age was 42 (21-82) in females and 48 (26-78) in males.

After the assessment visit, the operation was scheduled and performed under local anaesthesia and sedation in a day hospital program. Safena vein ablation was performed alone or with the adjunction of sclerotherapy or flebectomy in case needed.

All patients were discharged within 2 hours after treatment. Fourteen patients (0,8%) presented a post-operative bleeding from the puncture site or from associated flebectomy incision.

None needed surgical revision and all the cases were resolved with compression. Follow up visits were scheduled at 10 days, 30 days, 6 months and 1-year. Duplex scan was performed at each visit.

491 patients referred to some kind of discomfort during their first visit. In 263 cases (14,4%), Duplex scan revealed the presence of superficial vein phlebitis mainly localized in distal third of thigh mostly related with extra fascial safena.

Only 34 cases, at 30-day visit still complained of pain or stiffness in the

area and they underwent an extra follow up visit 2 months later, in which the majority referred to a complete lack of all symptomatology.

83 patients (4,5%) underwent a scheduled flebectomy for collaterals.

732 patients (40,2%) followed a program of spider vein sclerotherapy.

157 cases (6,9%) underwent recanalization, generally partial, of the safena; symptomatic patients were treated with foam sclerotherapy. Real-life results are similar to data published in literature. Adjunctive techniques may improve patient's satisfaction.

Keywords-Radiofrequency ablation, Varicose vein, Venefit

Biography

Ottorino Del Foco obtained his degree (Cum laude) in Medicine and Surgery at the University of Siena (Italy). He completed his PhD in Angiology and Vascular Surgery in Barcelona (Spain) in Santa Creu i San Pau Hospital. In 2010, after 8 years of practice in Torrecardena Hospital in Almeria, he formed a vascular unit in HLA Mediterraneo Hospital. In 2014, he became head of vascular department in Vithas Hospital Almeria. In January 2021, he joined Abu Dhabi Stem Cell Center in Abu Dhabi with the task to develop a regenerative treatment in no option CLI. He is member of the Spanish Society of Angiology and Vascular Surgery and the European Society of Vascular Surgery.

odelfoco@gmail.com